Last reviewed · How we verify
Tat protein
At a glance
| Generic name | Tat protein |
|---|---|
| Sponsor | Barbara Ensoli, MD |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Extended Follow-Up of the ISS T-003 Trial Volunteers (ISS T-003 EF-UP2020)
- Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein
- Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response In HIV Reservoir
- Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults (PHASE1)
- An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV (PHASE1)
- Impact of V106I on Resistance to Doravirine
- Therapeutic Vaccine for HIV (PHASE1)
- Effects of Maintaining Steady Albumin Levels (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tat protein CI brief — competitive landscape report
- Tat protein updates RSS · CI watch RSS
- Barbara Ensoli, MD portfolio CI